United States

Press Releases

Seqirus announces major advances in pandemic preparedness
Seqirus, a global leader in the prevention of influenza, announced today that the accelerated development of cell-based manufacturing technology at its state-of-the-art manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats. More.

Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market
Seqirus announced today it has begun shipping its portfolio of seasonal influenza vaccines to customers in the United States for the 2017-2018 influenza season. More.

Seqirus announces next major advancement in cell-based influenza vaccine technology
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, today announced the next major advancement in the use of cell-based technology at the state-of-the art manufacturing facility in Holly Springs, North Carolina. More.

Seqirus receives FDA approval for AFLURIA® QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older
Seqirus announced today that the US Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in persons 18 years of age and older. AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Both AFLURIA QUADRIVALENT and AFLURIA® (Influenza Vaccine), are available in the US for the 2016-2017 influenza season. More.

Seqirus to highlight new data in seasonal influenza prevention at Options IX for the Control of Influenza conference
Seqirus announced today that seven poster presentations reporting results of the company’s research and development in seasonal influenza prevention and control have been accepted at the Options IX for the Control of Influenza conference (Options IX) in Chicago, 24-28 August 2016. More.

Seqirus Presents Integrated Analyses for Trivalent Adjuvanted Seasonal Influenza Vaccine for Young Children
Seqirus today announced results of two data integrated analyses from six randomized clinical trials evaluating the safety and immunogenicity of its trivalent MF59-adjuvanted seasonal influenza vaccine in children aged six months to less than six years. 1,2 More.

Seqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season
Seqirus announced today that it has begun shipment of its portfolio of influenza vaccines to customers in the US market for the 2016-2017 season. More.

Seqirus receives FDA approval for FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) for people four years of age and older
“We are pleased to offer FLUCELVAX QUADRIVALENT, which is produced at our full-scale cell culture influenza vaccine manufacturing facility in North Carolina, to our valued customers during the 2016-2017 flu season.” More.

Seqirus Honored with National Award for Outstanding Efforts in Influenza Prevention
Seqirus announced today that the National Adult and Influenza Immunization Summit (NAIIS) awarded the organization with the 2016 Immunization Excellence Award for best Corporate Campaign. The accolade recognizes Seqirus’ creative and collaborative efforts to improve vaccination awareness and rates during the 2015-16 influenza season. The award was presented yesterday during the NAIIS Summit in Atlanta, Georgia. More.

The information presented on this site is intended for US residents only.
© 2017 Seqirus All rights reserved.
Seqirus is a trademark of CSL Limited.

BCSL14-02-0003 06/2014